Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA twice turned back applications for the drug/device combination product.
The post Supernus Wearable Device for Dosing Parkinson’s Drug Lands Long-Awaited FDA Approval appeared first on MedCity News.
